
General design of photocaged RuPHOTACs.
Image Credit: Phoebe Glazer
Scientific Frontline: Extended "At a Glance" Summary: RuPHOTACs (Ruthenium-based Photoactivated Chimeras)
The Core Concept: RuPHOTACs are light-activated molecular cages that keep protein-degrading drug molecules inactive until they are exposed to low-energy red light.
Key Distinction/Mechanism: While conventional proteolysis-targeting chimeras (PROTACs) degrade both diseased and healthy proteins systemically, RuPHOTACs utilize a ruthenium metal complex to physically block the drug from acting. Upon exposure to red light, the ruthenium cage is removed, allowing the PROTAC to selectively bind to disease-causing proteins and trigger their destruction only in the illuminated tissue.
Major Frameworks/Components:
- PROteolysis-Targeting Chimeras (PROTACs): Bifunctional catalyst molecules that simultaneously bind to a target protein and an E3 ubiquitin ligase enzyme, tagging the protein for natural cellular degradation.
- Ruthenium Photocages: A complex utilizing ruthenium, a transition metal, to block protein interactions until triggered by red light.
- Dendra2 Fusion Reporter System: A novel analytical strategy using a photoconvertible protein to accurately monitor and decouple true protein degradation rates from new protein synthesis in live, intact cells.


.jpg)
.jpg)



.png)
.png)




